Oral Bbpi Lb/Lv

Verify with FDA CVM →

21 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
21
Total Reports
1
Deaths Reported
480.0%
Death Rate

Active Ingredients

Oral Bbpi Lb/Lv

Administration Routes

Oral

Species Affected

Dog 21

Most Affected Breeds

Crossbred Canine/dog 5
Retriever - Labrador 4
Chihuahua 2
Terrier - Airedale 1
Retriever - Golden 1
Pointer - English Pointer 1
Pug 1
Poodle - Miniature 1
Siberian Husky 1
Shepherd Dog - Australian 1

Most Reported Reactions

Lethargy (see also Central nervous system depression in Neurological) 6
Hypersensitivity reaction 6
Facial swelling (see also Skin) 5
Emesis (multiple) 4
Vomiting 4
Hives (see also Skin) 4
Anaphylaxis 3
Stiffness NOS 3
Breathing difficulty 3
Panting 3
Abdominal discomfort 2
Gagging 2

Outcome Breakdown

Recovered/Normal
10 (47.6%)
Ongoing
8 (38.1%)
Outcome Unknown
2 (9.5%)
Died
1 (4.8%)

Data Summary

Metric Value
Total adverse event reports 21
Reports involving death 1
Case-fatality rate (reported events) 480.0%
Distinct species in reports 1
Distinct breeds in reports 13
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Oral Bbpi Lb/Lv Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 21 adverse event reports referencing Oral Bbpi Lb/Lv, including 1 reports in which the animal died — a 480.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Oral Bbpi Lb/Lv. Reported administration route is Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Oral Bbpi Lb/Lv reports are Dog (21 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (5), Retriever - Labrador (4), Chihuahua (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Oral Bbpi Lb/Lv are Lethargy (see also Central nervous system depression in Neurological) (6), Hypersensitivity reaction (6), Facial swelling (see also Skin) (5), Emesis (multiple) (4). Of the 21 reports with a coded outcome, Recovered/Normal is the leading category at 47.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Oral Bbpi Lb/Lv.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial